E-viri
PDF
Recenzirano
Odprti dostop
-
Engel, Julian; Lategahn, Jonas; Rauh, Daniel
ACS medicinal chemistry letters, 01/2016, Letnik: 7, Številka: 1Journal Article
In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clinical outcomes. However, the emergence of a newly discovered acquired drug resistance challenges the concept of small molecule targeted cancer therapy in NSCLC.
